All In Biotech

Drug Trial Radar · NCT06649110

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 232 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

232

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

Nov 29, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Conditions

  • Healthy Volunteers, Pulmonary Arterial Hypertension

Interventions

  • LTPDrug

    LTP001

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)Time frame: Baseline to Day 35
  2. Part B-Treatment Period 1: Change in pulmonary vascular resistance (PVR)Time frame: Baseline to Week 24
  3. Part B-Treatment Period 2: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)Time frame: From Day 1 until Week 106

Locations

87 sites in 18 countries. Site status is shown where the registry gives one.

  • Arizona Pulmonary Specialists Ltd

    Scottsdale, Arizona · Recruiting

  • UC Irvine Medical Center

    Orange, California · Recruiting

  • Stanford Medical Center

    Stanford, California · Recruiting

  • Univ Colorado Hospital

    Aurora, Colorado · Recruiting

  • Central Florida Pulmonary Group

    Orlando, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • U of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Norton Infectious Diseases Specialists

    Louisville, Kentucky · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts · Recruiting

  • Sky Integrative Medical Center SKYCRNG PPDS

    Ridgeland, Mississippi · Recruiting

  • Summit Health Eastside Clinic

    Bend, Oregon · Recruiting

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Statcare Pulmonary Consultants

    Knoxville, Tennessee · Recruiting

  • PPD Development LP

    Austin, Texas · Recruiting

  • PPD Development LP

    Austin, Texas · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • The University of Utah

    Salt Lake City, Utah · Recruiting

  • Pul Ass Richmond Inc P A R

    Richmond, Virginia · Recruiting

  • Novartis Investigative Site

    CABA, Argentina · Recruiting

  • Novartis Investigative Site

    Río Cuarto, Argentina · Recruiting

  • Novartis Investigative Site

    San Miguel de Tucumán, Argentina · Recruiting

  • Novartis Investigative Site

    Santa Fe, Argentina · Recruiting

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires F.D., Argentina · Recruiting

  • Novartis Investigative Site

    Camperdown, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Adelaide, South Australia, Australia · Recruiting

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, Belgium · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Prague, Czechia · Recruiting

  • Novartis Investigative Site

    Prague, Czechia · Recruiting

  • Novartis Investigative Site

    Brest, France · Recruiting

  • Novartis Investigative Site

    Clamart, France · Recruiting

  • Novartis Investigative Site

    Grenoble, France · Recruiting

  • Novartis Investigative Site

    Montpellier, France · Recruiting

  • Novartis Investigative Site

    Nice, France · Recruiting

  • Novartis Investigative Site

    Pessac, France · Recruiting

  • Novartis Investigative Site

    Poitiers, France · Recruiting

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.